In Brief: InControl, Inc.
This article was originally published in The Gray Sheet
Executive Summary
InControl, Inc.: Receives FDA investigational device exemption for U.S. clinical trials of its Metrix atrial defibrillation system, "the first implantable device designed specifically for patients suffering from recurrent symptomatic episodes of atrial fibrillation," the firm states. Initial studies will include 10 patients at four centers. Overseas trials began in October 1995...